7 Biotechnology Stocks to Buy Now

Popular Posts: 10 Oil and Gas Stocks to Buy Now15 Oil and Gas Stocks to Sell NowBiggest Movers in Energy Stocks Now – NGLS EXXI WTI TPLM Recent Posts: Biggest Movers in Healthcare Stocks Now – PBYI AGN PRGO EXAS Biggest Movers in Basic Materials Stocks Now – BCPC KS CMP WOR Hottest Technology Stocks Now – SUNE MLNX NSIT BRCD View All Posts 7 Biotechnology Stocks to Buy Now

This week, seven biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Top Valued Companies To Own For 2015

This week, Stemline Therapeutics, Inc. () is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). .

Pharmacyclics, Inc. () is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. .

The rating of Acorda Therapeutics, Inc. () moves up this week, rising from a C to a B. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. .

Northwest Biotherapeutics, Inc. () earns a B this week, jumping up from last week’s grade of C. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. .

BioMarin Pharmaceutical () is seeing ratings go up from a C last week to a B this week. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. .

Seattle Genetics, Inc. () gets a higher grade this week, advancing from a C last week to a B. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. .

Amgen () improves from a B to an A rating this week. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The stock has a dividend yield of 2.4%. .

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.